series-b
Stage
5
Investors
About
HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, with its initial program HIL-214 being a virus-like particle based vaccine candidate for preventing moderate-to-severe acute gastroenteritis caused by norovirus infection.
Explore HilleVax's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.